Royal DSM N.V. (DSM) invites owners of ordinary DSM shares to register their
shares in the period between 1 January and 28 February 2007 in the framework
of its intended loyalty dividend program.
Royal DSM N.V. has repurchased 241,180 of its own shares in the period from 7
December 2006 up to and including 11 December 2006 at an average price of EUR
36.28.
Krista Bruine de Bruin of the RSM Erasmus University of Rotterdam is the
winner of the 2006 DSM B2B Thesis Award for the thesis entitled ‘Double-handed
champions: Ambidextrous organizations’. Krista has won the sum of EUR 3,000
and the opportunity to present her thesis to Mr. Nico Gerardu, member of the
Managing Board of DSM.
Royal DSM N.V. has repurchased 641,045 of its own shares in the period from
November 30, 2006 up to and including December 6, 2006 at an average price of
EUR 36.13.
The Supervisory Board of Royal DSM N.V. has appointed Feike Sijbesma as
chairman of the Managing Board with effect from 1 May 2007. Mr. Sijbesma will
succeed Peter Elverding, who will retire with effect from the same date.
Royal DSM N.V. has repurchased 557,430 of its own shares in the period from
November 23, 2006 up to and including November 29, 2006 at an average price of
EUR 36.65.
Royal DSM N.V. has repurchased 493,000 of its own shares in the period from
November 16, 2006 up to and including November 22, 2006 at an average price of
EUR 37.43.
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced
that it has taken a share of 10% in the advanced materials company Micromuscle.
Royal DSM N.V. has repurchased 442,994 of its own shares in the period from
November 9, 2006 up to and including November 15, 2006 at an average price of
EUR 37.08.
Royal DSM N.V. has decided to build a new factory for waterborne coating
resins. This new plant will produce polyurethane dispersions to be marketed by
DSM Coating Resins and DSM NeoResins. Production will come on stream mid 2007.
The total investment costs are up to EUR 20 million.
Royal DSM N.V. has repurchased 582,575 of its own shares in the period from
November 2, 2006 up to and including November 8, 2006 at an average price of
EUR 36.46.
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced
that it has invested EUR 2 mln in IntegraGen, a French biotechnology company
specialized in the development and delivery of genetic tests for rapid
diagnosis and better (personalized) treatment of complex diseases.
Royal DSM N.V. has repurchased 967,604 of its own shares in the period from
October 26, 2006 up to and including November 1, 2006 at an average price of
EUR 35.89.
Royal DSM N.V. has repurchased 591,123 of its own shares in the period from
October 19, 2006 up to and including October 25, 2006 at an average price of
EUR 36.55.
At EUR 209 million, the Operating profit from continuing operations for the
third quarter of 2006 was slightly lower (EUR 6 million; 3%) than in the
excellent Q3 2005. Net profit amounted to EUR 140 million, down 7% from the
third quarter of 2005 (EUR 151 million).
Royal DSM N.V. has repurchased 538,017 of its own shares in the period from
October 12, 2006 up to and including October 18, 2006 at an average price of
EUR 35.98.
Today, the General Meeting of Shareholders appointed Mr Rolf-Dieter Schwalb as
Member of the Managing Board of Directors and Chief Financial Officer (CFO) of
DSM.
DSM is pleased to announce the appointment of Professor E.W. (Bert) Meijer, of
the Eindhoven University of Technology in the Netherlands, as chairman of its
new Scientific Advisory Board.
Royal DSM N.V. has repurchased 729,991 of its own shares in the period from
October 5 up to and including October 11, 2006 at an average price of EUR
35.83.
Royal DSM N.V. has repurchased 915,041 of its own shares in the period from
September 28 up to and including October 4, 2006 at an average price of EUR
34.72.
Royal DSM N.V. announces the acquisition of Lipid Technologies Provider AB
(LTP), a Swedish company with a technology platform based on formulated lipids.
A year ago DSM published its multi-year strategy: Vision 2010 – Building on
Strengths. During the annual analysts conference on 28 and 29 September 2006
DSM will give an update on the progress realized in the first year.
DSM Pharmaceutical Products, a Business Group of Royal DSM NV, has signed an
agreement with Albemarle Corporation of Baton Rouge (Louisiana-USA) regarding
the sale of the assets and business associated with DSM’s pharmaceutical
production site in South Haven (Michigan – USA).
Royal DSM N.V. today announces that it has decided to invest in a new facility
at its Jiangyin site, Jiangsu province, to produce high viscosity grades of
Akulon® polyamide 6 (PA6). The new plant is expected to come on stream in Q2
2008.
Royal DSM N.V., the largest manufacturer of high performance polyethylene
(HPPE) products in the world, today announces its decision to again invest in
new production capacity for Dyneema® fiber. The new unit will be built at
DSM’s facility in Greenville, North Carolina (USA).
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced
that it has invested USD 2 mln in Sol-Gel Technologies Ltd., a private
early-stage company committed to the development and commercialization of
safer and more effective healthcare products.
In the Dow Jones Sustainability World Index published today, DSM once again
tops the list for the Chemical Industry sector. This is the third year in a
row that DSM has been named the worldwide sustainability leader in the
chemical industry.
Alexander Wessels (42) has been appointed Business Group Director DSM Food
Specialties with effect from 1 October this year. He is currently Group
Director – Group Industrial Products at Campina.
DSM has today opened its new feed premix plant in Liaocheng in Shandong
province, China. The new facility demonstrates the company’s continuing
commitment to supporting China’s fast growing animal nutrition and health
industry.
The Supervisory Board of DSM is pleased to announce that it will propose to
appoint Rolf-Dieter Schwalb (54) as Member of the Managing Board of Directors
and Chief Financial Officer (CFO) of DSM as of October 1, 2006.
The European Commission has informed DSM that it has closed its investigations
into alleged violations of the anti-trust laws involving the EPDM sector
without charges of any kind against DSM or its affiliates.
Operating profit from continuing operations up 11% from Q2 2005, despite EUR
90 million increase in raw-material costs. Net profit up 18% to EUR 157
million. First half: sales up 9%, net profit up 20%. Outlook: full-year 2006
operating profit better than in record year 2005.
Jan-Paul de Vries, currently Business Group Director of DSM Composite Resins,
has been appointed Chief Marketing Officer and Corporate Vice President
Communications as of 1 November of this year.
Royal DSM N.V. today announces that it will start a de-bottlenecking project
for the acrylonitrile (ACN) plant located on the Chemelot site in Geleen, the
Netherlands.
Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and its
technology partner DSM Biologics BV, a business unit of Royal DSM N.V.,
announced today that Dr. Marco Cacciuttolo has accepted the position of Chief
Executive Officer of their joint PER.C6® R&D Center, which will be located in
Cambridge, MA.
Anton Robek, currently Business Unit Director of DSM Engineering Plastics
Europe, has been appointed Business Group Director DSM Melamine with effect
from 1 September of this year. In this position he will succeed Hans Dijkman,
who will take early retirement as of the same date.
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced
that it has invested USD 1.2 mln in the biomaterials company Oxford
Performance Materials (OPM).
At EUR 206 million, the Operating profit from continuing operations was EUR 24
million higher than in the first quarter of 2005. Net profit excluding
exceptional items amounted to EUR 140 million, up 7% from the first quarter of
2005. Net profit amounted to EUR 161 million, up 23% from Q1 2005 (EUR 131
million).
Royal DSM N.V. today announces the opening of its new compounding site for
engineering plastics at Jiangyin in the Jiangsu province of China on April 26,
2006.
Royal DSM N.V. has repurchased 1,535,000 of its own shares for an average
price of EUR 37.25 in order to cover the existing management and personnel
option plans in the manner that is customary at DSM.
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced
that it has participated in a follow-on financing round of 6.5 million USD in
the personalized nutrition company Sciona.
Royal DSM N.V. intends to repurchase a maximum of 1,850,000 of its own shares,
starting on March 31 until April 7, 2006, in order to cover its commitments
under existing management and personnel option plans in the manner that is
customary at DSM.
Yesterday, DSM’s shareholders at the Annual General Meeting approved the
proposed appointment of Mr Nico Gerardu as a member of DSM’s Managing Board of
Directors.
In conformity with the proposal made by the DSM Managing Board, the Annual
General Meeting of shareholders of Royal DSM N.V. has today resolved to
declare a dividend for 2005 of EUR 1.00 per ordinary share. This represents an
increase of about 15% compared with the dividends for previous years.
At today’s Annual General Meeting, starting at 14.00 hrs, Peter Elverding,
Chairman of the DSM Managing Board, will elucidate DSM’s current expectations
regarding the results for the first quarter of 2006.
It is DSM’s ambition to rank among the global top 25% of comparable companies
in terms of safety, health and environmental performance. To this end, the
company has set itself long-term environmental reduction targets.
DSM Desotech Inc., a subsidiary of Royal DSM N.V. based in the Netherlands,
and JSR Corporation announced today that the two companies have signed
definitive agreements that will result in JSR acquiring the display coatings
business that the two companies have jointly cooperated in as part of their
joint venture, Japan Fine Coatings Co., Ltd.
Royal DSM N.V. has repurchased 510,000 of its own shares on February 10, 2006
at an average price of EUR 35.98, in order to cover its commitments under
existing management and personnel option plans in the manner that is customary
at DSM.
Royal DSM N.V. intends to repurchase a maximum of 510,000 of its own shares in
February, starting 10 February, in order to cover its commitments under
existing management and personnel option plans in the manner that is customary
at DSM.
DSM has developed a new way to produce processed flavours that will bring
major benefits to customers. The company will invest in a new plant that will
be using new semi-continuous technology developed in unique cooperation
between DSM’s technology engineers and food technologists.
The bobsleighs to be used by the Dutch Olympic Team at the Olympic Games in
Turin contain special DSM vibration dampers that make the bobsleigh more
stable. This reduces the risk of steering errors and means that better times
can be achieved.
Royal DSM N.V., the Dutch chemicals group, and Sociedad Química y Minera de
Chile S.A. (SQM), today signed and closed the sale of the DSM business unit
Minera to SQM.
Royal DSM N.V. and Sociedad Química y Minera de Chile S.A. (SQM), today
confirm that they are discussing the possible sale of the DSM business unit
Minera to SQM.
The Managing Board of Directors of DSM announces that Mr Frans Pistorius (57)
has been appointed Director of DSM Nederland B.V. with effect from 1 May 2006.
